The Dutch Competition Authority extends its investigation into abuse of dominance by a manufacturer of orphan drug CDCA (Leadiant)
ACM extends its investigation into orphan drug CDCA-Leadiant*
The Netherlands Authority for Consumers and Markets (ACM) extends its investigation into the orphan drug CDCA manufactured by Leadiant. The investigation focuses on the question whether the manufacturer abuses a dominant position in the pricing of the drug. Background of the
Access to this article is restricted to subscribers
Already Subscribed? Sign-in
Access to this article is restricted to subscribers.
Read one article for free
Sign-up to read this article for free and discover our services.